FLGT - This News Just Put Fulgent at the Top of My Buy List
Genetic testing company Fulgent Genetics (NASDAQ: FLGT) has had a wild ride over the past few years. At the beginning of the pandemic, Fulgent experienced parabolic revenue growth when it was able to pivot from its core, next-generation sequencing (NGS) business to produce COVID-19 tests. As one might imagine, this sent the stock straight up in early 2021 with shares topping out at more than $183.
It's been a different story since then with the stock having fallen almost 70% from that high. At the time of this writing, its shares trade for $60. However, a recent press release contained a few pieces of information that have placed Fulgent at the top of my buy list.
Image source: Getty Images.
For further details see:
This News Just Put Fulgent at the Top of My Buy List